

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2359)

PROPOSED ELECTION OF EXECUTIVE DIRECTOR

Reference is made to the relevant announcement of WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the “**Company**”) dated March 23, 2022 in relation to, among other things, the Proposed Amendments to the Articles of Association (the “**Announcement**”). Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

With a view to further improve the enhance the capability and standard of the board (the “**Board**”) of directors of the Company (the “**Directors**”) in terms of decision-making, as well as to optimize the corporate governance of the Company, the Company proposed to increase the number of Board members from 12 to 13.

The Board has resolved to, subject to the passing at the annual general meeting of the Company to be convened in due course (the “**AGM**”) by the Shareholders of the special resolution in connection with the Proposed Amendments to the Articles of Association regarding the abovementioned increase in the number of Board members to 13, nominate Dr. Minzhang Chen (陳民章博士) (“**Dr. Chen**”) as an executive Director of the second session of the Board for a term commencing on the date on which his election is approved by the Shareholders (being the date of the AGM) and ending on the expiry of the term of the second session of the Board (the “**Term**”), and he may seek re-election upon expiry of the Term. The biographical details of Dr. Chen, who is currently a co-chief executive officer of the Company, are set out as follows:

Dr. Minzhang Chen (陳民章), aged 52, joined the Group in 2008 and has served in senior managerial roles in various important departments of the Group. He is currently a co-chief executive officer of the Company, and has established WuXi Chemistry, the chemistry business segment of the Company, through leading and integrating subsidiaries and business units including Shanghai SynTheAll Pharmaceutical Co., Ltd. (“**WuXi STA**”) and the Chemistry Service Unit. Dr. Chen has had over 20 years of experience in the research and development and production management of new drugs, and he has demonstrated important impact on the process of multiple global new drug research and development and commercialization. Prior to joining the Company, Dr. Chen served as the chief researcher of the chemistry department of Schering-Plough Research Institute (先靈葆雅研究所) and the head of the technical operation department of Vertex Pharmaceuticals Inc.

Dr. Chen obtained a bachelor’s degree in chemistry from Peking University (北京大學) in the PRC in 1991. He also obtained a Ph. D. degree in Organic Chemistry from University of Minnesota in the U.S. in 1996.

As at the date of this announcement, Dr. Chen has an interest in (i) 131,644 H Shares pursuant to awards granted to him under the H share award and trust schemes adopted by the Company, as well as (ii) 146,180 A Shares which comprise Restricted A Shares granted to him under the Restricted A Shares and Stock Option Incentive Plan of 2019 of the Company. For further details, please refer to (i) the announcements of the Company dated July 21, 2020, December 16, 2020, August 3, 2021 and December 15, 2021; (ii) the circulars of the Company dated August 12, 2020 and August 10, 2021; and (iii) the poll results announcements of the Company dated August 31, 2020 and August 30, 2021.

Subject to the approval by the Shareholders at the AGM, the Company will enter into a service contract with Dr. Chen in respect of his election as an executive Director for the Term. In addition, the remuneration of Dr. Chen as an executive Director shall be in line with the remuneration policy for the Directors for the second session of the Board as approved by the Shareholders at the the annual general meeting of the Company held on May 15, 2020 pursuant to which the remuneration of executive Directors who hold positions in the Company shall be determined by his or her existing remuneration package with the Company.

Save as disclosed above, there are no other matters in relation to the proposed election of Dr. Chen which would require disclosure under Rule 13.51(2) of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited or matters which ought to be brought to the attention of the shareholders of the Company.

In this regard, an ordinary resolution will be proposed at the AGM to consider and approve the proposed election of Dr. Chen as an executive Director.

GENERAL

A circular containing, among other things, further details of the proposed election of Dr. Chen as an executive Director and a notice of the AGM, will be despatched to the Shareholders in due course

By order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman

Hong Kong, March 23, 2022

As of the date of this announcement, the Board of the Company comprises Dr. Ge Li, Mr. Edward Hu, Dr. Steve Qing Yang, Mr. Zhaohui Zhang and Dr. Ning Zhao as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Dr. Jiangnan Cai, Ms. Yan Liu, Mr. Dai Feng, Dr. Hetong Lou and Mr. Xiaotong Zhang as independent non-executive Directors.

* *For identification purposes only*